First-in-human treatment with J-Valve TAVI device
JC Medical, Inc. has announced the treatment of the first patient with the company’s Transfemoral TAVI device, the J-Valve TF System for aortic regurgitation. The first patient was treated at St. Paul’s Hospital – Vancouver, Canada by John Webb, MD, FACC, FSCAI, Director of Interventional Cardiology. There are currently no transcatheter valves approved for the treatment of pure aortic regurgitation in the U.S., Canada, or Europe.
Failing aortic valves make up a significant portion of patients with heart failure, a major public health problem with a prevalence of over 1.5 million in the U.S. and over 18 million worldwide.
JC Medical’s J-Valve Systems are designed to restore normal blood flow out of the heart and into the body, which may improve symptoms of heart failure such as shortness of breath, fatigue and chest pain.
The devices feature a proprietary anchor mechanism that does not require calcification for fixation and that is flexibly linked to a self-expanding stent frame to uniquely attach to the failing native heart valve.
“We are very pleased that our J-Valve could help this patient. We developed the J-Valve to be reliable and easy to use,” said Ji Zhang, M.D., founder and Chief Executive Officer of JC Medical.
“We thank the physician group who has recognised this unique clinical solution. With approximately 2% of the elderly population having heart failure due to a defective stenotic aortic valve and 1% due to a regurgitant valve, this leads to a significant decrease in the quality of life, the loss of life for many, and costs the healthcare system billions of dollars annually. We look forward to further exploring the promise of J-Valve and its role in treating failing aortic heart valves.”